Welcome to our dedicated page for CELLBXHEALTH PLC news (Ticker: ANPCY), a resource for investors and traders seeking the latest updates and insights on CELLBXHEALTH PLC stock.
CelLBxHealth plc, formerly known as ANGLE plc and represented in the United States as ANGLE PLC S/ADR (symbol ANPCY), regularly issues news updates that describe its progress in circulating tumour cell (CTC) intelligence and liquid biopsy. Company announcements highlight developments around its Parsortix® platform, collaborations with pharmaceutical and medtech partners, and strategic decisions affecting its business direction and branding.
News items often cover clinical and scientific milestones, such as proof-of-concept studies in indications like glioblastoma and integrations of the Parsortix workflow with established diagnostic platforms, including Roche Tissue Diagnostics’ BenchMark ULTRA system. Releases also describe participation in major oncology and drug development conferences, where the company presents data on CTC detection, biomarker analysis and potential applications in areas such as antibody-drug conjugate development.
Investors and researchers following ANPCY-related news will also see updates on commercial contracts and collaborations. The company has reported completing contracts with large pharmaceutical companies, ongoing services agreements with biopharma partners, and a collaboration with Myriad Genetics to adapt an existing tissue-based cancer test to a CTC-based format using Parsortix. Interim results and strategy updates provide context on revenue mix between pharma services and product sales, as well as commentary on external market conditions.
Corporate governance and board or management changes are another recurring theme. Recent announcements include the transition from ANGLE plc to CelLBxHealth plc, the appointment of an Executive Chairman, subsequent changes to the board, and later the appointment of a Chief Executive Officer and additional non-executive directors. These updates are presented alongside information on funding plans and cash runway.
For readers tracking ANPCY, the news stream offers a consolidated view of how CelLBxHealth is advancing CTC-based technologies, engaging with global partners, and refining its strategy in response to scientific opportunities and market conditions.
CelLBxHealth (OTC:ANPCF) will discontinue maintenance of its FDA establishment license and device listing for the Parsortix system to align regulatory costs with current commercial usage and strengthen cost discipline. More than 97% of fielded Parsortix platforms are used for in-house translational research and assay development, where a device listing offers no commercial benefit. The company says it will reallocate savings to revenue growth, customer support, and product development and can reinstate the listing by paying annual fees if commercial conditions change. The change is said to have no impact on sales pipeline, market forecasts, customer support, or ongoing partnerships.
CelLBxHealth (OTCQX->Pink: ANPCF) announced preliminary unaudited FY2025 results and further cost rationalisation on 16 January 2026. The company expects FY2025 revenue of approximately £1.4m with Q4 revenue ~£0.4m; ~£0.2m of sales were deferred into Q1 2026. Cash at 31 Dec 2025 was £7.3m. The business is consolidating Guildford operations, reducing headcount, and expects annualised cost savings of £5.9m. Ordinary shares were voluntarily delisted from OTCQX (last trade 31 Dec 2025) and began trading on the Pink Limited Market on 2 Jan 2026. Management cites a qualified 2026/27 sales pipeline of £12.6m (risk-weighted £4.5m) that underpins revenue targets. Final audited FY2025 results remain subject to change.
CelLBxHealth plc (OTC:ANPCF) announced board changes effective immediately on 12 January 2026. Peter Collins was appointed Chief Executive Officer and Klaas de Boer, Kim Oreskovic and Benjamin Hart were appointed as Non-Executive Directors. Separately, Non-Executive Director Joseph Eid will step down from the board, effective 31 January 2026. The announcement states required AIM Rule 17 and Schedule 2(g) information is provided and that the disclosure is deemed inside information under the EU Market Abuse Regulation.
Cellbxhealth (OTC:ANPCF) disclosed a major holding notification: Conifer Management, L.L.C. crossed a threshold on 18-Dec-2025 and was notified to the issuer on 22-Dec-2025. The resulting situation shows Conifer holds 29.900% of voting rights, equating to 340,681,395 voting rights in Cellbxhealth. Shares are held in private funds managed by Conifer Management. The filing names Pershing LLC as the shareholder vehicle and lists Gregory Alexander as ultimate controlling person.
CelLBxHealth (OTCQX:ANPCY / AIM:CLBX; ADR symbol ANPCF) presented a proof-of-concept study at the 16th World ADC Conference (Nov 3-6, 2025) showing the Parsortix® platform and CellKeep slide are compatible with Roche Tissue Diagnostics' BenchMark ULTRA automated IHC workflow.
Key points: blood samples and fixed cancer cell lines were processed and sent to Roche for automated IHC analysis using HER2, TROP2, and PSMA assays; BenchMark ULTRA staining was reported compatible with CelLBxHealth's manual immunofluorescent workflow; the release highlights CTCs as dynamic biomarkers that may support ADC patient selection.
CelLBxHealth (OTCQX:ANPCF) welcomed an international expert consensus published 4 November 2025 that affirms the clinical relevance of circulating tumor cells (CTCs) and highlights the Parsortix® platform.
The consensus of 32 experts found that CTCs provide information distinct from ctDNA, 90% of respondents expect CTC testing to become routine within five years, and 40% identified Parsortix as the most promising next‑generation technology. The company also updated funding: cash runway into early 2026 and an intention to raise about £6m, with a fundraise announcement expected by early December 2025.
ANGLE plc (OTCQX:ANPCY) announced senior leadership changes on 16 October 2025: Peter Collins is appointed interim Chief Executive Officer and Klaas de Boer joins as a senior advisor to the Board. The company will be renamed CelLBxHealth plc.
Collins brings >25 years in oncology diagnostics and drug-development roles, joining in a non‑board capacity. De Boer brings >25 years of venture and finance experience and multiple board roles; the company said his experience will support a restructure and funding planned for Q4 2025. The announcement also lists investor relations contacts and advisors.
ANGLE plc (AIM:AGL / OTCQX:ANPCY) announced a strategic refocus and management change on 8 October 2025. Dr Jan Groen moves from Non-Executive Chairman to Executive Chairman to lead a revised strategy centred on CTC intelligence and accelerated commercial traction using the Parsortix platform. The company proposes a name change to CelLBxHealth plc and an AIM ticker change to CLBX, expected mid-October.
The plan emphasises proteomics and genomics applications, tighter cost control and partnerships. Cash runway is stated through to Q1 2026, and the company expects a need to raise funds in the coming months. CEO and Finance Director will transition out over the next 12 months, with contractual entitlements honoured.
ANGLE plc (OTCQX:ANPCY) presented promising data from a proof-of-concept study in glioblastoma at the 7th Advances in Circulating Tumour Cells meeting. The study, using their Parsortix® system and CellKeep™ slides, demonstrated significant capabilities in detecting circulating tumor cells (CTCs) in glioblastoma patients.
Key findings showed CTCs were detected in 60% of patients, with CTC clusters observed in 78% of CTC-positive patients. The study revealed that 73% of subjects showed extracellular vesicles (EVs), highlighting the potential for liquid biopsy in monitoring glioblastoma. Notably, the system's label-free methodology successfully detected mesenchymal phenotype CTCs, which are typically undetectable using traditional CTC technologies.
ANGLE plc (OTCQX:ANPCY), a leading liquid biopsy company specializing in circulating tumour cell (CTC) solutions, announced significant leadership changes. CEO Andrew Newland and Finance Director Ian Griffiths have agreed to step down from their positions on the Board following discussions with a major shareholder.
The current Board consists of Dr. Jan Groen as Non-executive Chairman and Dr. Joseph Eid as Non-executive Director. The company plans to expand its Board membership in the future. Both departing executives have committed to supporting an orderly transition.